glp 1 cardiovascular disease GLP-1 Agonists in Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies Stopping GLP-1 drugs can quickly

One-carbon metabolism during the menstrual cycle and pregnancy

The landmark Diabetes Prevention Program (DPP) trial found that metformin participants lost an average of 2.1kg (about 2% of body weight) over 2.8 years

Some earlier studies have suggested these drugs may have anti-inflammatory and neuroprotective effects that could help protect eye health

The Prescribing Clinician's Obligations If a parent or adolescent patient asks specifically about ipamorelin, the responsible clinical response involves four concrete steps: Confirm that no FDA-approved indication exists and that no pediatric safety data have been published [2]